InvestSMART

Bioxyne Limited (ASX:BXN)

ALERT: Price-sensitive ASX Announcement for BXN
Current share price for BXN : $0.930 0.856 (1,156.76%)+
Release
21 May 2026 5:38PM
Price at Release
$0.074
Full Release
download
Summary
The document is a Notice of General Meeting for Bioxyne Limited, scheduled for 19 June 2026, to discuss and vote on two main resolutions. The first resolution is to change the company name to BLS Pharmaceuticals Limited, and the second is to consolidate the company's issued capital on a 10:1 basis. The meeting will be held at Addisons in Sydney, and shareholders are encouraged to vote by proxy ahead of the meeting. The notice includes an Explanatory Memorandum and Proxy Form, providing detailed instructions for voting and proxy appointment, alongside a timetable for the capital consolidation process.
Key Points
  • Notice of General Meeting for Bioxyne Limited to be held on 19 June 2026.
  • Discussion of changing the company's name to BLS Pharmaceuticals Limited.
  • Proposal to consolidate capital on a 10:1 basis.
  • Shareholders encouraged to vote by proxy in advance.
  • Timetable for the consolidation of capital provided.
  • Detailed instructions on how to vote and appoint a proxy.
  • Resolution 1 requires approval for the change of company name.
  • Resolution 2 requires approval for consolidation of capital.
  • The meeting will be held at Addisons, Sydney.
  • Explanatory Memorandum and Proxy Form included.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.